The objective of this study was to determine the factors associated with the occurrence of arterial vascular events in a multiethnic systemic lupus erythematosus (SLE) cohort. The PROFILE cohort, comprised SLE patients (n = 1333) of defined ethnicity from five different US institutions, was studied to determine demographic, clinical and biological variables associated with vascular events. An arterial vascular event (first episode) was either a myocardial infarction, angina pectoris and/or a vascular procedure for myocardial infarction, stroke, claudication and/or evidence of gangrene. Patient characteristics were analyzed by univariable and multivariable Cox proportional hazards regression analyses. One-hundred twenty-three (9.8%) patients had at least one incident arterial event. Age at cohort enrollment (HR = 1.04, 95% CI 1.03-1.06), smoking (HR = 2.20, 95% CI 1.40-3.46) and the CRP2* C alleles (HR = 1.91, 95% CI 1.04-3.49) were associated with a shorter time-to-the occurrence of arterial vascular events. Some clinical manifestations of disease activity were associated with a shorter time-to-occurrence [psychosis (HR = 2.21, 95% CI 1.10-4.44), seizures (HR = 1.85, 95% CI 1.00-3.24) and anaemia (HR = 1.83, 95% CI 1.02-3.31)], but others were not [arthritis (HR = 0.32, 95% CI 0.18-0.58)]. In conclusion, older patients, especially in the context of a predisposing environmental factor (smoking) and severe clinical manifestations, are at higher risk of having arterial vascular events. The genetic contribution of the variation at the CRP locus was not obscured by demographic or clinical variables. Awareness of these factors should lead to more effective management strategies of patients at risk for arterial vascular events. Lupus (2009) 18, 958-965.
Introduction
There is strong evidence that systemic lupus erythematosus (SLE) patients have a markedly increased risk of cardiovascular disease, [1] [2] [3] [4] which is a major cause of late deaths among these patients. [5] [6] [7] [8] Hospitalisations due to cardiovascular disease are also more frequent among lupus patients 9 and represent an important source of health-related expenditures among them.
Most studies of arterial vascular events, whether thrombotic or atherosclerotic in nature, have focused on their prevalence, [10] [11] [12] [13] [14] their pathogenesis [15] [16] [17] [18] [19] [20] [21] [22] [23] or their sociodemographic features. 4, 8, 10, 11, 24 We undertook this study to identify clinical and biological factors, including certain CRP gene polymorphisms, associated with arterial vascular events in PROFILE, a large multiethnic SLE cohort. We hypothesized that ethnic and genetic background, as well as specific clinical manifestations, would be associated with the occurrence of arterial vascular events. These data may be important in the identification of patients at high risk for such events and may allow the design of preventive strategies that may beneficially impact the morbidity and mortality associated with them in patients with SLE. 10 Patients and methods PROFILE is a multiethnic, multicentre prospective cohort of SLE patients. 25 This cohort was constituted in 1998 by combining the existing cohorts at Northwestern University, Johns Hopkins University, the University of Alabama at Birmingham, the University of Texas Health Science Center at Houston and the University of Puerto Rico. The Institutional Review Board of each institution approved this study, and written informed consent was obtained from all participating subjects according to the Declaration of Helsinki.
PROFILE patients meet the American College of Rheumatology (ACR) revised and updated criteria 26, 27 
Variables
The PROFILE database consists of variables common to the individual cohorts identified after carefully mapping the different cohorts' databases. 25 Socioeconomic-demographic variables included age at cohort enrollment, gender and ethnicity. Clinical variables included current smoking status, hypertension (recording of three abnormal readings and/or the use of antihypertensive medications), cumulative SLErelated clinical manifestations from diagnosis to the time of the occurrence of an arterial vascular event and damage assessed at baseline by the Systemic Lupus International Collaborating Clinics Damage Index (SDI). 28 For these analyses, items included in the definition of arterial vascular events were excluded from the SDI. Lupus manifestations included were those described in the ACR classification criteria as well as selected clinical manifestations from the SDI domains. Antiphospholipid (aPL) antibodies including anticardiolipin IgM and IgG antibodies (by enzyme-linked immunosorbent assays) and/or the lupus anticoagulant (using activated partial thromboplastin time or Russel viper venom time assays), obtained at each site at study enrollment, and CRP gene alleles, which have been shown to associate with SLE, cardiovascular disease and CRP levels, were assayed or genotyped using standard laboratory techniques and appropriate primers as previously discussed. [29] [30] [31] Cumulative exposure to glucocorticoids, hydroxychloroquine, cyclophosphamide, methotrexate, mycophenolate mofetil, azathioprine and low-dose aspirin were also examined.
Outcome variable
Consistent with the SDI, arterial vascular events were documented if myocardial infarction, angina pectoris and/or a vascular procedure for myocardial infarction (coronary artery bypass graft), cerebral vascular accident and claudication lasting ≥ 6 months and/or evidence of gangrene or significant tissue loss (loss of a digit or a limb) had occurred. Only the first incident event was examined. By definition, these events were recorded in the SDI only if 6 months had elapsed lapsed since the diagnosis of SLE had been made.
Statistical analyses
First, descriptive analyses were performed to compare the sociodemographic, clinical manifestations, immunologic and genetic features, disease damage and treatments received in patients with and without vascular events. The relationship between variables was examined by Student's t-tests or Chi-square tests, as appropriate. Next, the association between variables and time-to-the occurrence of the first arterial vascular event (or events if two events occurred at the same time) was examined by univariable and multivariable analyses. First, univariable Cox proportional hazards regressions were examined, and all variables with a p value ≤ 0.10 in these analyses plus gender, ethnicity and disease duration at enrollment were then entered into a multivariable Cox proportional hazards regression model in which the dependent variable was time-to-the occurrence of arterial vascular events (prediction model). In an alternative (association) model, medications were included if p ≤ 0.10 in the univariable analyses. With the resultant hazard ratios (HR), a HR ≥ 1 indicates a shorter time-to-event occurrence and a HR < 1 indicates a longer time-to-event occurrence. All analyses were performed using SAS software, version 9.1 (SAS Institute, Cary, North Carolina, United States).
Results
A total of 1333 patients were included in these analyses. As expected, patients were predominantly women (90.4%) with a mean age [mean (standard deviation, SD)] of 35.7 (12. 3) years. All ethnic groups were represented, 139 (10.4%) were Texan Hispanics, 102 (7.7%) were Puerto Rican Hispanics, 472 (35.4 %) were African-Americans and 620 (46.5%) were Caucasians. The mean (SD) years of education of the PROFILE cohort was 13.7 (2.8) years, 88.5% had healthcare insurance and 61.6% were employed. Factors indicative of low socioeconomic status were more frequently seen for patients enrolled at the University of Texas Health Science Center at Houston; the mean (SD) years of education was 11.6 (3.2), 60.4% had health insurance, and 38.9% were employed. A total of 117 (9.8%) patients had at least one arterial vascular event. Among these events, 29 were myocardial infarctions, 32 were angina pectoris and/or coronary artery bypass graft, 85 were strokes and 4 were peripheral artery disease; 19 patients had two events (stroke and MI or angina, n = 7 and myocardial infarction and angina, n = 12), whereas four patients had three events (stroke, myocardial infarction and claudication or angina), but, as already noted, only the first event was considered in these analyses. Table 1 shows the sociodemographic features, cumulative clinical manifestations, genetic features, disease damage and pharmacologic treatments in patients with and without arterial vascular events. Patients with vascular events were older (42.3 ± 15.2 vs 34.9 ± 11.8, p < 0.001) and had longer disease duration at enrollment (2.9 ± 4.0 vs 1.9 ± 3.2, p = 0.0007) than those without vascular events. Patients with arterial vascular events were more likely (p < 0.05) to smoke cigarettes, to have discoid rash, valvular heart disease, hypertension, psychosis, seizures and anaemia, and to receive treatment with intravenous glucocorticoids, azathioprine, cyclophosphamide and low-dose aspirin than patients without vascular events. In addition, patients with arterial vascular events had higher SDI scores (2.11 ± 2.50 vs 1.08 ± 1.63, p < 0.001).
Univariable analyses
Hazard ratios and 95% confidence intervals (95% CI) for the time-to-the-occurrence of arterial vascular events are depicted in 
Discussion
Arterial vascular events remain a common cause of morbidity and mortality among patients with SLE. 3, 4, 6, 7, 32 Using the PROFILE database, we have examined the risk factors for these events using a timeto-the event approach. In this cohort of 1333 SLE patients, we found that nearly 10% of patients 3 despite the fact that more than half of the patients in our study were of non-Caucasian ethnicity.
We have also confirmed the association between arterial vascular events and age, cigarette smoking and certain clinical manifestations of disease severity. In addition, we have found the genetic variation in the CRP locus (rs1800947) linked with these arterial vascular events, an association not previously described for lupus patients. Cigarette smoking, the most important preventable cause of premature death in the United States, 33, 34 was associated with a shorter time-to-the occurrence of arterial vascular events. In SLE, cigarette smoking has been identified both as a risk factor for the development of the disease 35 and as a disease modifier. For example, cigarette smoking has been associated with progression of lupus nephritis to end-stage renal disease 36 and with higher degrees of disease activity. 37 More recently, it has also been recognised as a risk factor for both arterial 24, 38, 39 and venous thrombotic events 40 and as a modulator of the therapeutic response to antimalarial therapy, 41, 42 which has a protective effect against cardiovascular disease. 38 Cigarette smoking may contribute to these events through several different mechanisms including the formation of oxidized low-density lipoprotein cholesterol, enhancement of a pro-thrombotic state, activation of the sympathetic nervous system and impaired prostacyclin production and endothelium-dependent vasodilation. 43 A low-grade systemic inflammatory response occurs in chronic cigarette smokers, 43, 44 which may act synergistically with the chronic inflammatory process that characterises SLE. Whatever the mechanism, smoking cessation is a mandatory prevention measure in lupus patients.
We have previously identified age as a risk factor for the development of venous thrombotic events and arterial vascular events in a subset of patients within the PROFILE cohort. 40 Similarly, in a Canadian lupus cohort, 11 patients with both arterial and venous thrombotic events were older than those patients who had not developed these events. Although the effect was modest in PROFILE, it is likely that risk factors for cardiovascular disease, as occur in the general population, continue to accrue throughout the life span giving a higher probability for their occurrence with age.
The fact that clinical manifestations of serious disease such as psychosis and seizures were associated with arterial events may be an indicator that those patients with more active disease are at higher risk of suffering these events. Furthermore, both psychosis 45 and seizures 46 can be clinical manifestations of cerebral ischemia. They are also recognised neurological manifestations of the aPL syndrome, 47 probably reflecting occlusion of the cerebral microvasculature. Anaemia may compound this tendency 48 and reflect, in part, damage accrual, which was also associated with a shorter time-to-the occurrence of arterial vascular events, even after excluding the items of the definition of arterial vascular events.
Several studies have now established that alleles within the CRP gene can influence CRP protein levels. 30 The CRP gene consists of two exons and one intervening intron that contains a polymorphic GT n repeat. Previously, we performed molecular typing of the CRP GT n and found that the intron encoding 20 repeats (GT 20 ) was associated with arterial vascular events in SLE patients, particularly for African-American and Hispanic patients. 31 Also, the CRP promoter variants and the C allele of the synonymous SNP rs1800947 (CRP2) have been associated with basal CRP levels. 30, 49, 50 Now, we are reporting the association of the C allele of the synonymous SNP rs1800947 (CRP2) with a shorter time-to-the occurrence of arterial vascular events. The lack of association with the promoter variant (including the variants associated with CRP levels, rs3093062 and the triallelic rs309244) may reflect statistical power given the minor allele frequencies. In general, the role of rs18000947 in cardiovascular disease is not well understood. Because CRP seems to be both a marker and a direct participant in cardiovascular disease, CRP genotypes associated with an increase on its synthesis may have an important role in the pathogenesis of atherosclerosis. However, rs1800947 is linked with decreased CRP promoter activity and hence decreased levels of CRP. 50 Despite this fact some studies have shown an association of rs1800947 with an elevated risk of cardiovascular disease, particularly in Europeandescent 51 and Japanese populations. 52 Conversely, others have reported either no association with nonfatal myocardial infarctions and strokes, 50 or a decreased prevalence of coronary artery disease, the latter in Mexican Americans. 53 A study comparing this CRP polymorphism in lupus and non-lupus patients with arterial vascular events may help to elucidate if this allele confers a distinct risk to SLE patients.
Although it is entirely possible that medications may, to a certain extent, exert some effect in the occurrence of arterial vascular events, with hydroxychloroquine being protective 45 and being glucocorticoids detrimental, 40 we could not include medications in our prediction model as the timing of their use is not uniformly available in all of the individual cohorts constituting PROFILE. Thus, the observed increased risk for low-dose aspirin should be interpreted as an associated occurrence and not as a predictor. Unlike most studies on cardiovascular disease in SLE, 10, 13, 15, 16, 54, 55 we failed to show any significant association with aPL antibodies. One possible explanation for our results is that the assays used to test aPL antibodies were not homogenous across the constituent cohort centres; however, even when aPL antibodies were assessed longitudinally over time in the Hopkins cohort, this association could not be shown. Similarly, although the HR for hypertension in the univariable analyses suggested a shorter timeto-the occurrence of arterial vascular events, this variable was not retained in the multivariable model. Nevertheless, the importance of hypertension as a risk factor for the occurrence of arterial vascular events should not be dismissed. Contributions of ethnicity, a variable also found to be a risk factor for cardiovascular disease not only in lupus patients 10 but also in the general population, 56, 57 were not evident in our model suggesting that smoking, certain clinical manifestations and CRP alleles convey strong associations.
We recognise that this study is not without some limitations. The fact that PROFILE is not a true inception cohort may have precluded identifying the predictors of their occurrence. We also recognise that complete assessment of disease activity, assessed over time, may be an important risk factor for arterial vascular events. Because disease activity was measured by different instruments in these cohorts, the possibility of examining all components of activity in all patients taken together was precluded. Similarly, previous smoking history and other important risk factors for arterial vascular events such as dyslipidemia, 10 diabetes mellitus and serial high-sensitivity CRP levels 24, 40 were not available uniformly in all patients. Systematic evaluation of these factors and thrombophilic risk factors, such as hyperhomocysteinemia, 15, 21, 23 antiprothrombin antibodies 17, 58 and other inherited and acquired thrombophilic conditions, 59 is an important future goal. Nonetheless, we have identified important factors contributing to the development of arterial vascular events. Older patients, smokers, those with severe neurologic manifestations and those with a predisposing genetic background (alleles of the CRP2 locus) are at higher risk for the occurrence of these events. Assessing the risk for arterial vascular events among lupus patients should be part of the routine clinical practice, and assessment of CRP genetics may be a useful adjunct to modification of environmental factors such as smoking cessation.
